Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013.

Background: There are limited large case series of peristomal pyoderma gangrenosum (PPG), an uncommon cause of recalcitrant peristomal ulceration.Objective: We sought to further characterize the clinical features, causes, treatments, and outcomes of PPG.Methods: We conducted a retrospective chart re...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of the American Academy of Dermatology Vol. 75; no. 5; pp. 931 - 940
Autores principales: Barbosa, Naiara S., Tolkachjov, Stanislav N., el-Azhary, Rokea A., Davis, Mark D.P., Camilleri, Michael J., McEvoy, Marian T., Bridges, Alina G., Wetter, David A.
Formato: Journal Article
Publicado: Elsevier B.V. Nov2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=118813337&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 118813337
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01909622
        1ZF
      jtl: Journal of the American Academy of Dermatology
      issn: 01909622
      maglogo: N
    pubinfo:
      dt: Nov2016
      vid: 75
      iid: 5
      pid: 467
      pub: Elsevier B.V.
      place: New York, New York
    artinfo:
      ui:
        118813337
        118813337
        NLM27473454
        10.1016/j.jaad.2016.05.044
        NLM27473454
        118813337
      ppf: 931
      ppct: 9
      formats:
      tig:
        atl: Clinical features, causes, treatments, and outcomes of peristomal pyoderma gangrenosum (PPG) in 44 patients: The Mayo Clinic experience, 1996 through 2013.
      aug:
        au:
          Barbosa, Naiara S.
          Tolkachjov, Stanislav N.
          el-Azhary, Rokea A.
          Davis, Mark D.P.
          Camilleri, Michael J.
          McEvoy, Marian T.
          Bridges, Alina G.
          Wetter, David A.
        affil: Department of Dermatology, Mayo Clinic, Rochester, Minnesota
      sug:
        subj:
          Pyoderma Gangrenosum Etiology
          Postoperative Complications Etiology
          Ostomy Adverse Effects
          Adult
          Pyoderma Gangrenosum Surgery
          Female
          Pyoderma Gangrenosum Epidemiology
          Postoperative Complications Epidemiology
          Immunosuppressive Agents Adverse Effects
          Skin Ulcer Etiology
          Risk Factors
          Retrospective Design
          Antibiotics Therapeutic Use
          Biological Products Adverse Effects
          Male
          Immunoglobulins, Intravenous Therapeutic Use
          Inflammatory Bowel Diseases Surgery
          Skin Ulcer Epidemiology
          Adolescence
          Aged, 80 and Over
          Drug Therapy, Combination
          Middle Age
          Pyoderma Gangrenosum Diagnosis
          Postoperative Complications Drug Therapy
          Diagnostic Errors
          Adrenal Cortex Hormones Therapeutic Use
          Immunocompromised Host
          Recurrence
          Postoperative Complications Surgery
          Aged
          Disease Susceptibility
          Young Adult
          Reoperation
          Skin Ulcer Drug Therapy
          Biological Products Therapeutic Use
          Pyoderma Gangrenosum Drug Therapy
          Scales
          Adult: 19-44 years
          Adolescent: 13-18 years
          Aged, 80 & over
          Middle Aged: 45-64 years
          Aged: 65+ years
          Female
          Male
      ab: Background: There are limited large case series of peristomal pyoderma gangrenosum (PPG), an uncommon cause of recalcitrant peristomal ulceration.Objective: We sought to further characterize the clinical features, causes, treatments, and outcomes of PPG.Methods: We conducted a retrospective chart review of patients with PPG seen at Mayo Clinic from January 1996 to July 2013.Results: A total of 44 patients had PPG (mean age, 46 years; 32 women [73%]); 41 (93%) had inflammatory bowel disease. Mean time to PPG onset after stoma surgery was 5.2 months (excluding 1 outlier). Systemic therapies included corticosteroids (66%), immunosuppressants (41%), biologics (36%), and a combination of systemic treatments (36%). Mean time to reach a complete response was 10.7 weeks. Stoma closure had the greatest complete response (4 of 4 patients, no recurrences). Recurrence after any treatment was documented in 23 of 38 (61%) patients. Stoma relocation/revision recurred in 10 of 15 (67%) patients. Remission occurred in 29 of 31 (94%) patients.Limitations: Small sample size and retrospective study design are limitations.Conclusion: PPG is strongly associated with inflammatory bowel disease, is predominant in women, and has a prolonged time to onset and high recurrence rate. Systemic corticosteroid or combination therapies and surgical closure can be effective treatments. Timely recognition and management are paramount to achieving early remission.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N